telitacicept + tofacitinib

This is a **combination therapy** composed of telitacicept and tofacitinib, investigated for the treatment of refractory rheumatoid arthritis (RA), particularly in patients who have failed traditional disease-modifying antirheumatic drugs (DMARDs) and at least two biologic/targeted synthetic DMARDs[1][7]. - **Telitacicept** is a recombinant fusion protein that acts as a dual inhibitor of B lymphocyte stimulator (BLyS, also known as BAFF) and a proliferation-inducing ligand (APRIL), targeting B-cell mediated autoimmunity and thereby reducing autoantibody production[3][4]. - **Tofacitinib** is an oral small molecule inhibitor of Janus kinase 1 (JAK1) and Janus kinase 3 (JAK3), suppressing cytokine-driven inflammation via blocking the JAK-STAT signaling pathway[2][8]. Combining these drugs addresses both **B-cell dysregulation** (via telitacicept) and **T-cell/cytokine-mediated inflammation** (via tofacitinib), providing a multi-target approach for difficult-to-treat RA[4]. The combination is being explored in a real-world observational study for their additive or synergistic effects on disease activity, safety, and joint outcomes in D2T RA patients[1][7].